메뉴 건너뛰기




Volumn 67, Issue 2, 2007, Pages 131-139

Plasma Aβ levels as predictors of response to rivastigmine treatment in Alzheimer's disease

Author keywords

amyloid; Alzheimer's disease; Plasma; Rivastigmine

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CHOLINESTERASE INHIBITOR; RIVASTIGMINE; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; CARBAMIC ACID DERIVATIVE; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

EID: 34447526671     PISSN: 00651400     EISSN: 00651400     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (14)

References (42)
  • 2
    • 0036355751 scopus 로고    scopus 로고
    • Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine
    • Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S (2002) Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord 14: 156-160.
    • (2002) Dement Geriatr Cogn Disord , vol.14 , pp. 156-160
    • Basun, H.1    Nilsberth, C.2    Eckman, C.3    Lannfelt, L.4    Younkin, S.5
  • 3
    • 23744462680 scopus 로고    scopus 로고
    • Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
    • Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, Nagel J, Lane R (2005) Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 21: 1317-1327.
    • (2005) Curr Med Res Opin , vol.21 , pp. 1317-1327
    • Bullock, R.1    Touchon, J.2    Bergman, H.3    Gambina, G.4    He, Y.5    Rapatz, G.6    Nagel, J.7    Lane, R.8
  • 4
    • 33645214870 scopus 로고    scopus 로고
    • Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease
    • Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J, Lane R (2006) Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 22: 483-494.
    • (2006) Curr Med Res Opin , vol.22 , pp. 483-494
    • Bullock, R.1    Bergman, H.2    Touchon, J.3    Gambina, G.4    He, Y.5    Nagel, J.6    Lane, R.7
  • 5
    • 0029896202 scopus 로고    scopus 로고
    • A simple and efficient method for apolipoprotein E genotype determination
    • Chapman J, Estupinan J, Asherow A (1996) A simple and efficient method for apolipoprotein E genotype determination. Neurology 46:1484-1485.
    • (1996) Neurology , vol.46 , pp. 1484-1485
    • Chapman, J.1    Estupinan, J.2    Asherow, A.3
  • 8
    • 0035099794 scopus 로고    scopus 로고
    • A method for estimating progression rates in Alzheimer Disease
    • Doody RS, Hassman P, Dunn K (2001) A method for estimating progression rates in Alzheimer Disease. Arch Neurol 58: 449-454.
    • (2001) Arch Neurol , vol.58 , pp. 449-454
    • Doody, R.S.1    Hassman, P.2    Dunn, K.3
  • 10
    • 0033961398 scopus 로고    scopus 로고
    • Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil
    • Evans M, Ellis A, Watson D, Chowdhury T (2000) Sustained cognitive improvement following treatment of Alzheimer's disease with donepezil. Int J Geriatr Psychiatry 15: 50-53.
    • (2000) Int J Geriatr Psychiatry , vol.15 , pp. 50-53
    • Evans, M.1    Ellis, A.2    Watson, D.3    Chowdhury, T.4
  • 11
    • 0035106966 scopus 로고    scopus 로고
    • Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
    • Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R (2001) Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol 58: 417-422.
    • (2001) Arch Neurol , vol.58 , pp. 417-422
    • Farlow, M.R.1    Hake, A.2    Messina, J.3    Hartman, R.4    Veach, J.5    Anand, R.6
  • 12
    • 25844457652 scopus 로고    scopus 로고
    • Biochemical markers and risk factors of Alzheimer's disease
    • Flirski M, Sobow T (2005) Biochemical markers and risk factors of Alzheimer's disease. Curr Alzheimer Res 2: 47-64.
    • (2005) Curr Alzheimer Res , vol.2 , pp. 47-64
    • Flirski, M.1    Sobow, T.2
  • 13
    • 0032797870 scopus 로고    scopus 로고
    • Donepezil. Pharmacoeconomic implications of therapy
    • Foster RH, Plosker GL (1999) Donepezil. Pharmacoeconomic implications of therapy. Pharmacoeconomics 16: 99-114.
    • (1999) Pharmacoeconomics , vol.16 , pp. 99-114
    • Foster, R.H.1    Plosker, G.L.2
  • 14
    • 12144290725 scopus 로고    scopus 로고
    • Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins
    • Hoglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K (2004) Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol 61: 333-337.
    • (2004) Arch Neurol , vol.61 , pp. 333-337
    • Hoglund, K.1    Wiklund, O.2    Vanderstichele, H.3    Eikenberg, O.4    Vanmechelen, E.5    Blennow, K.6
  • 15
    • 21544467552 scopus 로고    scopus 로고
    • Cholinesterase inhibitors for patients with Alzheimer's disease: Systematic review of randomized clinical trials
    • Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H (2005) Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomized clinical trials. BMJ 331: 321-327.
    • (2005) BMJ , vol.331 , pp. 321-327
    • Kaduszkiewicz, H.1    Zimmermann, T.2    Beck-Bornholdt, H.P.3    van den Bussche, H.4
  • 16
    • 0031917730 scopus 로고    scopus 로고
    • Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: Relationship to dementia severity
    • Kaufer DI, Cummings JL, Christine D (1998) Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 10: 55-63.
    • (1998) J Neuropsychiatry Clin Neurosci , vol.10 , pp. 55-63
    • Kaufer, D.I.1    Cummings, J.L.2    Christine, D.3
  • 17
    • 0034489269 scopus 로고    scopus 로고
    • Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease
    • Lahiri DK, Farlow MR, Hintz N, Utsuki T, Greig NH (2000) Cholinesterase inhibitors, beta-amyloid precursor protein and amyloid beta-peptides in Alzheimer's disease. Acta Neurol Scand Suppl 176: 60-67.
    • (2000) Acta Neurol Scand , Issue.SUPPL. 176 , pp. 60-67
    • Lahiri, D.K.1    Farlow, M.R.2    Hintz, N.3    Utsuki, T.4    Greig, N.H.5
  • 19
    • 0037222763 scopus 로고    scopus 로고
    • Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease
    • Lanctot KL, Herrmann N, LouLou MM (2003b) Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. J Psychiatry Neurosci 28: 13-26.
    • (2003) J Psychiatry Neurosci , vol.28 , pp. 13-26
    • Lanctot, K.L.1    Herrmann, N.2    LouLou, M.M.3
  • 20
    • 0033823002 scopus 로고    scopus 로고
    • Galantamine: Additional benefits to patients with Alzheimer's disease
    • Lilienfeld S, Parys W (2000) Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord 11: 19-27.
    • (2000) Dement Geriatr Cogn Disord , vol.11 , pp. 19-27
    • Lilienfeld, S.1    Parys, W.2
  • 21
    • 0034027804 scopus 로고    scopus 로고
    • How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis
    • Livingston G, Katona C (2000) How useful are cholinesterase inhibitors in the treatment of Alzheimer's disease? A number needed to treat analysis. Int J Geriatr Psychiatr 15: 203-207.
    • (2000) Int J Geriatr Psychiatr , vol.15 , pp. 203-207
    • Livingston, G.1    Katona, C.2
  • 22
    • 0030036648 scopus 로고    scopus 로고
    • Apolipoprotein E genotype allele epsilon4 and response to tacrine in Alzheimer's disease
    • Lucotte G, Oddoze C, Michel B-F (1996) Apolipoprotein E genotype allele epsilon4 and response to tacrine in Alzheimer's disease. Alzheimer's Res 2: 101-102.
    • (1996) Alzheimer's Res , vol.2 , pp. 101-102
    • Lucotte, G.1    Oddoze, C.2    Michel, B.-F.3
  • 23
    • 0032709113 scopus 로고    scopus 로고
    • The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
    • Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL (1999) The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol 56: 1388-1393.
    • (1999) Arch Neurol , vol.56 , pp. 1388-1393
    • Mega, M.S.1    Masterman, D.M.2    O'Connor, S.M.3    Barclay, T.R.4    Cummings, J.L.5
  • 28
    • 3042858052 scopus 로고    scopus 로고
    • Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease
    • Ritchie CW, Ames D, Clayton T, Lai R (2004) Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 12: 358-369.
    • (2004) Am J Geriatr Psychiatry , vol.12 , pp. 358-369
    • Ritchie, C.W.1    Ames, D.2    Clayton, T.3    Lai, R.4
  • 29
    • 0031883716 scopus 로고    scopus 로고
    • A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group
    • Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT (1998) A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50: 136-145.
    • (1998) Neurology , vol.50 , pp. 136-145
    • Rogers, S.L.1    Farlow, M.R.2    Doody, R.S.3    Mohs, R.4    Friedhoff, L.T.5
  • 32
    • 0005872618 scopus 로고    scopus 로고
    • Severity of Alzheimer's disease and response to cholinergic therapy
    • Schneider LS, Farlow MR (1996) Severity of Alzheimer's disease and response to cholinergic therapy. Eur J Neurol 3: 238.
    • (1996) Eur J Neurol , vol.3 , pp. 238
    • Schneider, L.S.1    Farlow, M.R.2
  • 33
    • 30944461183 scopus 로고    scopus 로고
    • Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer's disease
    • Sobow T, Kloszewska I (2005) Short-term treatment with rivastigmine and plasma levels of Ab peptides in Alzheimer's disease. Folia Neuropathol 43: 340-344.
    • (2005) Folia Neuropathol , vol.43 , pp. 340-344
    • Sobow, T.1    Kloszewska, I.2
  • 34
    • 33847794764 scopus 로고    scopus 로고
    • Cholinesterase inhibitors in mild cognitive impairment: A meta-analysis of randomized controlled trials
    • Sobow T, Kloszewska I (2007) Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. Neurol Neurochir Pol. 41: 13-21.
    • (2007) Neurol Neurochir Pol , vol.41 , pp. 13-21
    • Sobow, T.1    Kloszewska, I.2
  • 35
    • 1842503058 scopus 로고    scopus 로고
    • Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease
    • Sobow T, Flirski M, Liberski PP (2004) Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease. Acta Neurobiol Exp (Wars) 64: 53-70.
    • (2004) Acta Neurobiol Exp (Wars) , vol.64 , pp. 53-70
    • Sobow, T.1    Flirski, M.2    Liberski, P.P.3
  • 36
    • 21044447551 scopus 로고    scopus 로고
    • Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease
    • Sobow T, Flirski M, Kloszewska I, Liberski PP (2005) Plasma levels of alpha beta peptides are altered in amnestic mild cognitive impairment but not in sporadic Alzheimer's disease. Acta Neurobiol Exp (Wars) 65: 117-124.
    • (2005) Acta Neurobiol Exp (Wars) , vol.65 , pp. 117-124
    • Sobow, T.1    Flirski, M.2    Kloszewska, I.3    Liberski, P.P.4
  • 37
    • 0344238739 scopus 로고    scopus 로고
    • Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients
    • Stefanova E, Blennow K, Almkvist O, Hellstrom-Lindahl E, Nordberg A (2003) Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients. Neurosci Lett 338: 159-163.
    • (2003) Neurosci Lett , vol.338 , pp. 159-163
    • Stefanova, E.1    Blennow, K.2    Almkvist, O.3    Hellstrom-Lindahl, E.4    Nordberg, A.5
  • 38
    • 13944276825 scopus 로고    scopus 로고
    • Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective
    • Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555.
    • (2005) Cell , vol.120 , pp. 545-555
    • Tanzi, R.E.1    Bertram, L.2
  • 39
    • 0034627263 scopus 로고    scopus 로고
    • Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomized controlled trial. Galantamine International-1 Study Group
    • Wilcock GK, Lilienfeld S, Gaens E (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. Galantamine International-1 Study Group. BMJ 321: 1445-1449.
    • (2000) BMJ , vol.321 , pp. 1445-1449
    • Wilcock, G.K.1    Lilienfeld, S.2    Gaens, E.3
  • 40
    • 5344240284 scopus 로고    scopus 로고
    • Amyloid-beta precursor protein processing in neurodegeneration
    • Wilquet V, De Strooper B (2004) Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 14: 582-588.
    • (2004) Curr Opin Neurobiol , vol.14 , pp. 582-588
    • Wilquet, V.1    De Strooper, B.2
  • 41
    • 2642567691 scopus 로고    scopus 로고
    • Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease
    • Zhang X (2004) Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease. Curr Drug Targets CNS Neurol Disord 3: 137-152.
    • (2004) Curr Drug Targets CNS Neurol Disord , vol.3 , pp. 137-152
    • Zhang, X.1
  • 42
    • 17444414627 scopus 로고    scopus 로고
    • Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients
    • Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M (2005) Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 19: 237-242.
    • (2005) Neurobiol Dis , vol.19 , pp. 237-242
    • Zimmermann, M.1    Borroni, B.2    Cattabeni, F.3    Padovani, A.4    Di Luca, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.